Skip to content

Sign in Start free

Create your free account

Loading your page…

We care for the people who care.

No ads. No selling of your data. No third-party trackers.

Apps

Prognia
Ward
Suture
Osler

Library

Guidelines
Medicines
Articles
Calculators
Explore decks
Institutions
Blog

Prognia

About
Pricing
Contact

Support us

Founders Wall

© 2026 Prognia · Amsterdam, the NetherlandsPrivacy TermsExchangeRate-API

Medicines · US (FDA)
Antidepressants

FDA 2023

Other antidepressants

Levomilnacipran

Approved 12 Jan 2023OralCapsule, extended release

The FDA lists this product in 8 strengths and forms.

Official labelAsk Osler about it

On this page

Composition
Strengths and forms
Official product information

The table holds no label text for this product yet, only the facts beside it. The official product information has the full text.

Composition

Active ingredients: LEVOMILNACIPRAN 80MG

Strengths and forms

The FDA lists each strength of a product separately; these pages share one label.

LEVOMILNACIPRAN 80MG · Capsule, extended releaseThis page
LEVOMILNACIPRAN 20MG · Capsule, extended releaseANDA210857-001 · Tentative approval
LEVOMILNACIPRAN 120MG · Capsule, extended releaseANDA210857-004 · Tentative approval
LEVOMILNACIPRAN 40MG · Capsule, extended releaseANDA210857-002 · Tentative approval
LEVOMILNACIPRAN 40MG · Capsule, extended releaseANDA210805-002 · Tentative approval
LEVOMILNACIPRAN 80MG · Capsule, extended releaseANDA210805-003 · Tentative approval
LEVOMILNACIPRAN 20MG · Capsule, extended releaseANDA210805-001 · Tentative approval
LEVOMILNACIPRAN 120MG · Capsule, extended releaseANDA210805-004 · Tentative approval

Official product information

Drugs@FDA lists the approved labels, letters and reviews for application ANDA210857.

More in antidepressants

Vortioxetine HydrobromideTablet

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Brand name: Levomilnacipran
Drug class: Other antidepressants
Group: Antidepressants
Route: Oral
Dosage form: Capsule, extended release
Applicant: Zydus Pharms USA Inc
Status: Tentative approval
FDA approval: 12 Jan 2023
Application: ANDA210857-003
RxCUI: 1433212

Guidelines

Guidelines in psychiatry293 guidelines in the library

FDA 2023

Doxepin HydrochlorideCream

FDA 2023SafinamideTablet

FDA 2019Zulressobrexanolone · Solution

FDA 2019Spravatoesketamine hydrochloride · Spray

FDA 2015Dextromethorphan Hydrobromide and Quinidine Sulfatedextromethorphan hydrobromide · Capsule

FDA 2015Milnacipran HydrochlorideTablet

FDA 2015Guaifenesin and Dextromethorphan Hydrobromidedextromethorphan hydrobromide · Tablet, extended release

FDA 2015Desvenlafaxine SuccinateTablet, extended release

FDA 2013Duloxetine HydrochlorideCapsule, delayed rel pellets

FDA 2013Khedezladesvenlafaxine · Tablet, extended release

FDA 2013Rasagiline MesylateTablet

FDA 2013Brisdelleparoxetine mesylate · Capsule

FDA 2013Fluvoxamine MaleateCapsule, extended release

FDA 2013DesvenlafaxineTablet, extended release

FDA 2012Olanzapine and Fluoxetine Hydrochloridefluoxetine hydrochloride · Capsule

FDA 2012Escitalopram OxalateSolution

FDA 2010Fluoxetine HydrochlorideCapsule, delayed rel pellets